---
layout: post
title: "The Use of Published Literature in Support of New Animal Drug Approvals; Guidance for Industry; Availability"
date: 2026-02-05 18:35:55 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-05333
original_published: 2023-03-16 00:00:00 +0000
significance: 8.00
---

# The Use of Published Literature in Support of New Animal Drug Approvals; Guidance for Industry; Availability

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** March 16, 2023 00:00 UTC
**Document Number:** 2023-05333

## Summary

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a final guidance for industry #106 entitled "The Use of Published Literature in Support of New Animal Drug Approvals." This guidance replaces existing guidance #106, "The Use of Published Literature in Support of New Animal Drug Approvals," which FDA published in August 2000. It addressed the use of a single scientific article to support drug approval. This revision of the guidance document considers multiple uses of the scientific literature, including narrative reviews, systematic reviews, and meta-analyses to support approval of a new animal drug.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/03/16/2023-05333/the-use-of-published-literature-in-support-of-new-animal-drug-approvals-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2023-05333

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
